Related Experiment Video
Updated: May 9, 2026

MicroRNA-based Regulation of Picornavirus Tropism
Published on: February 6, 2017
Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity
Taisuke Izumi1, Ryan Burdick, Mayu Shigemi
1Viral Mutation Section.
Abstract:
Mov10 and APOBEC3G (A3G) localize to cytoplasmic granules called processing bodies (P bodies), incorporate into human immunodeficiency virus type 1 (HIV-1) virions, and inhibit viral replication. The functional relevance of Mov10/A3G P-body localization to virion incorporation and antiviral activity has not been fully explored. We found that a helicase V mutant of Mov10 exhibits significantly reduced localization to P bodies but still efficiently inhibits viral infectivity via virion incorporation. Disruption of the P bodies by DDX6 knockdown also confirmed Mov10 antiviral activity without P-body localization. In addition, overexpression of SRP19, which binds to 7SL RNA, depleted A3G from P bodies but did not affect its virion incorporation. Sucrose gradient sedimentation assays revealed that the majority of Mov10, A3G, HIV-1 RNA, and Gag formed high-molecular-mass (HMM) complexes that are converted to low-molecular-mass (LMM) complexes after RNase A treatment. In contrast, the P-body markers DCP2, LSM1, eIF4e, DDX6, and AGO1 were in LMM complexes, whereas AGO2, an effector protein of the RNA-induced silencing complex that localizes to P bodies, was present in both LMM and HMM complexes. Depletion of AGO2 indicated that RNA-induced silencing function is required for Mov10's ability to reduce Gag expression upon overexpression, but not its virion incorporation or effect on virus infectivity. We conclude that the majority of Mov10 and A3G are in HMM complexes, whereas most of the P-body markers are in LMM complexes, and that virion incorporation and the antiviral activities of Mov10 and A3G do not require their localization to P bodies.
Insights
Mov10 and APOBEC3G (A3G) inhibit HIV-1 replication and are found in virions. Their antiviral activity and incorporation into virions do not depend on P-body localization, challenging previous assumptions.
Area of Science:
- Virology
- Molecular Biology
- Cell Biology
Background:
- Mov10 and APOBEC3G (A3G) are known to localize to processing bodies (P bodies) and inhibit HIV-1 replication.
- The precise role of P-body localization in the antiviral functions of Mov10 and A3G, including virion incorporation, remains unclear.
Purpose of the Study:
- To investigate the functional significance of Mov10 and A3G P-body localization for their antiviral activities and virion incorporation.
- To elucidate the molecular complexes and cellular localization of Mov10 and A3G during HIV-1 replication.
Main Methods:
- Mutagenesis of Mov10 to assess the role of its helicase domain in P-body localization and antiviral activity.
- Knockdown of P-body components (DDX6) and other proteins (SRP19, AGO2) to evaluate their impact on Mov10/A3G function.
- Sucrose gradient sedimentation assays to analyze the molecular mass of Mov10, A3G, and associated viral/cellular factors.
Main Results:
- A Mov10 helicase mutant showed reduced P-body localization but retained antiviral activity via virion incorporation.
- Disruption of P bodies did not abolish Mov10's antiviral effects.
- Mov10 and A3G predominantly form high-molecular-mass (HMM) complexes, distinct from low-molecular-mass (LMM) P-body markers.
- Virion incorporation and antiviral activity of Mov10 and A3G are independent of P-body localization.
Conclusions:
- The functional antiviral activities and virion incorporation of Mov10 and A3G are not dependent on their localization to P bodies.
- Mov10 and A3G exist in distinct high-molecular-mass complexes separate from canonical P-body components.
- These findings redefine the understanding of Mov10 and A3G's mechanism of HIV-1 inhibition.
Related Concept Videos
Retroviruses
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes
Retrovirus Life Cycles
Non-LTR Retrotransposons
Subviral Agents

